Landos’ advanced AI-based integrated computational LANCE platform explores immune cell activity and metabolic function, a distinct approach that has verified two novel pathways currently in clinical development: LANCL2 and NLRX1. Activation of the LANCL2 pathway amplifies the immunosuppressive functions of T regulatory cells while decreasing production of inflammatory cytokines such as TNF-alpha. NLRX1, a second pathway discovered by Landos, provides a mechanism for modulating immune functions to complement or act in combination with other related treatments.
Identifying Novel
Pathways at the
Interface of Immunity
and Metabolism
We are committed to
the discovery and
development of
first-in-class, oral
therapeutics for
patients with
autoimmune disease
Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune disease. BT-11, Landos’ lead asset, is completing a Phase 2 trial in mild to moderate ulcerative colitis (UC) in the U.S. Europe and Russia, with plans to initiate a Phase 2 trial of BT-11 in moderate to severe Crohn’s disease (CD). BT-11 is a small molecule that targets a novel immunometabolic pathway within the gastrointestinal tract, potentially providing a more effective treatment and an improved patient tolerability profile.
Reprogramming Immune Responses in Autoimmune Disease
Aiming to Bring Safer,
More Effective
Therapies to Patients
with IBD
For chronic conditions such as inflammatory bowel disease, current treatments bear adverse side effects and impact on patients’ quality of life. Landos Biopharma’s translational research is focused on identifying more precise targets for treating ulcerative colitis and Crohn’s disease. Landos’ therapeutic approach aims to enhance the treatment paradigm of debilitating autoimmune disease by preventing or reducing patient susceptibility to infections and other side effects common with current therapies.
At Landos Biopharma, our mission is to
be bold and uncover new mechanisms of
treating autoimmune disease.
News
1/4
Landos Biopharma Announces Positive Results from a Phase 2 Trial of Oral BT-11 for Patients with Ulcerative Colitis
Read More7/14
Landos Biopharma Announces First Human Dosing in a Phase 1 Study of NX-13, its Novel Candidate for Inflammatory Bowel Disease
Read More5/12
Landos Biopharma to Present at Two Upcoming Investor Conferences
Read More